Inspira Technologies Oxy B.H.N. Ltd. (IINN)
Automate Your Wheel Strategy on IINN
With Tiblio's Option Bot, you can configure your own wheel strategy including IINN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IINN
- Rev/Share 0.0
- Book/Share 0.2334
- PB 3.3844
- Debt/Equity 0.1516
- CurrentRatio 2.0208
- ROIC 0.0023
- MktCap 20239247.0
- FreeCF/Share -0.5151
- PFCF -2.122
- PE -1323.3765
- Debt/Assets 0.0812
- DivYield 0
- ROE -0.0022
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Inspira's ART100 in Use at Tier-1 U.S. Hospitals, Generating Strong Clinical Interest and Accelerating Sales Discussions
Published: June 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
RA'ANANA, Israel, June 11, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, announced today that its FDA-cleared ART100 system adoption has begun to positively impact commercialization interest and efforts, representing a key milestone and significantly contributes to the Company's commercial validation.
Read More
CORRECTION - Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
RA'ANANA, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- RA'ANANA, Israel, June 5, 2025 -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced preparations for scaled-up its production capabilities for its U.S. Food and Drug Administration (FDA)-cleared INSPIRA™ ART100 system (the “ART100 system”), in response to expected demand from a European governmental authority with which the Company is currently in advanced-stage procurement negotiations.
Read More
Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
RA'ANANA, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has scaled-up its production capabilities for its U.S. Food and Drug Administration (FDA)-cleared INSPIRA™ ART100 system (the “ART100 system”), in response to expected demand from a European governmental authority with which the Company is currently in advanced-stage procurement negotiations.
Read More
Inspira Technologies Initiates Global Commercial Rollout of FDA-Cleared ART100 System
Published: May 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
Following successful clinical implementations in the U.S., Inspira accelerates commercialization of its system. The Company is already engaged in discussions with governmental health departments and private organizations Following successful clinical implementations in the U.S., Inspira accelerates commercialization of its system. The Company is already engaged in discussions with governmental health departments and private organizations
Read More
INSPIRA ART100 System Approved by Israel's Largest Healthcare Provider for Use in Organ Transplant Patients
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
RA'ANANA, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that the INSPIRA™ ART100 has been approved by Israel's largest healthcare provider to undergo a clinical validation by leading physicians who intend to use the innovative life-support and diagnostic device during organ transplant procedures. As part of this advancement, Inspira will deploy the U.S. Food and Drug Administration (“FDA”) approved INSPIRA ART100 system at one of Israel's renowned medical centers affiliated with the largest health care provider.
Read More
Inspira Technologies Generates First Revenues from Deployment of INSPIRA ART100 Systems
Published: April 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
The Company achieves significant milestone with initial revenues generated from FDA-cleared life support technology deployed in a leading U.S. healthcare facility; additional systems currently planned for second hospital facility The Company achieves significant milestone with initial revenues generated from FDA-cleared life support technology deployed in a leading U.S. healthcare facility; additional systems currently planned for second hospital facility
Read More
Inspira Technologies Announces Successful Installation of INSPIRA ART100 Systems in Premier U.S. Hospital
Published: March 25, 2025 by: PRNewsWire
Sentiment: Neutral
Inspira's innovative FDA-cleared INSPIRA™ ART100 system was successfully deployed at premier U.S. hospital, with systems in place for clinical use RA'ANANA, Israel , March 25, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has successfully completed the installation, training program and operational readiness for its INSPIRA ART100 system for cardiopulmonary bypass procedures at one of New York's premier hospitals.
Read More
Inspira Achieves Positive Results of Above 95% For Preventing Bloodstream Infections
Published: February 11, 2025 by: PRNewsWire
Sentiment: Neutral
The ex-vivo testing demonstrated significant bacterial reduction for the innovative IV dressing technology aimed at preventing bloodstream infections in critical patients RA'ANANA, Israel , Feb. 11, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in breakthrough life-support technology, today announced positive initial results from its previously reported collaboration with Ennocure MedTech Ltd.
Read More
About Inspira Technologies Oxy B.H.N. Ltd. (IINN)
- IPO Date 2021-07-14
- Website https://inspira-technologies.com
- Industry Medical - Devices
- CEO Mr. Dagi Shahar Ben-Noon
- Employees 37